Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002635 · ClinicalTrials.gov registry record · Phase 2

Aminocamptothecin in Treating Patients With T-cell Lymphoma

A Phase 2 study of Lymphoma, sponsored by Yale University.

Completed
Registry status
Phase 2
Development phase
12
Enrollment target
3
Study locations

NCT00002635 is a Phase 2 study of Lymphoma that has completed, run by Yale University. The registered enrollment target is 12 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002635, a Phase 2 study of Lymphoma, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 2
Development phase
12 participants
Enrollment target
3
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with advanced cutaneous T-cell lymphoma.

Conditions Studied

Lymphoma

Interventions

  • BIOLOGICAL filgrastim
  • DRUG aminocamptothecin

Study Locations (3)

Connecticut

  • Yale Comprehensive Cancer Center - New Haven

Illinois

  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago

Massachusetts

  • New England Medical Center Hospital - Boston

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 1995-05
Est. Completion 2000-04
Phase Phase 2

Sponsor

Yale University

1,492 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00002635

The ClinicalTrials.gov registry entry for NCT00002635 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which filgrastim is the first listed.

NCT00002635 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Connecticut, Illinois, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00002635 about?

NCT00002635 is a clinical study titled "Aminocamptothecin in Treating Patients With T-cell Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with advanced cutaneous T-cell lymphoma.

What is the current status of trial NCT00002635?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 1995-05. Estimated completion is 2000-04.

What conditions does trial NCT00002635 study?

This clinical trial studies the following conditions: Lymphoma.

What interventions are being tested in trial NCT00002635?

The interventions under investigation include: filgrastim (BIOLOGICAL), aminocamptothecin (DRUG).

Who is sponsoring clinical trial NCT00002635?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002635 being conducted?

This trial has 3 study locations across Connecticut, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.